Insilico Medicine's AI-Driven NLRP3 Inhibitors Set to Revolutionize Drug Market
Insilico Medicine has made significant strides in the development of NLRP3 inhibitors, with its AI-driven drug discovery platform LEGION. The company aims to make NLRP3 a lucrative target, similar to GLP-1 receptor agonists, which are projected to reach $471.1 billion by 2031.
LEGION, developed by Insilico's founder and CEO Alex Zhavoronkov, has identified over 34,000 unique scaffolds with potential to bind NLRP3, expanding to nearly 94,000 after simplification. This AI tool uncovered promising molecular structures in hours, not months, and has generated over 123 billion new molecular structures in a proof-of-concept test.
Insilico has open-sourced over 120 million molecules designed to target NLRP3, making regions of chemical space harder to patent. The company's preprint 'Molecular LEGION' aims to efficiently search drug molecule space and prevent 'me too' drugs. LEGION is designed to cover the drug molecule universe, preventing rivals from patenting knockoffs and expanding generative chemistry tools' reach.
With the NLRP3 market expected to grow significantly by 2033, Insilico plans to submit an IND application for its oral NLRP3 inhibitor ISM8969 later this quarter. This potential best-in-class, brain-penetrant, and safe treatment could revolutionize various diseases involving NLRP3.
Read also:
- Medical professional advocates for increased action to address deficiency of primary care physicians
- Treating hypertension can potentially add a decade to a person's life span.
- Unveiled Accounts of Female Scientists Whose Genius Remained Unnoticed
- Yucatan Health Official Accused of Extortion, Business Groups Demand Justice
